Facebook tracking pixel
C72.9
ICD-10-CM
Ependymoma

Find information on Ependymoma diagnosis, including Spinal Ependymoma, Intraventricular Ependymoma, and Myxopapillary Ependymoma. Learn about clinical documentation requirements, medical coding guidelines, and healthcare best practices for Ependymoma. This resource provides details relevant to medical professionals involved in diagnosing and managing Ependymoma.

Also known as

Spinal Ependymoma
Intraventricular Ependymoma
Myxopapillary Ependymoma

Diagnosis Snapshot

Key Facts
  • Definition : Ependymoma is a tumor arising from ependymal cells lining the brain ventricles and spinal cord central canal.
  • Clinical Signs : Symptoms vary by location, including headaches, nausea, vomiting, back pain, weakness, and balance problems.
  • Common Settings : Diagnosis involves neurological exam, MRI, and biopsy. Treatment often includes surgery, radiation, and chemotherapy.

Related ICD-10 Code Ranges

Complete code families applicable to AAPC C72.9 Coding
C72.3

Ependymoma of spinal cord

Malignant tumor of the ependymal cells lining the spinal cord.

C71.3

Ependymoma of brain

Malignant tumor arising from ependymal cells within the brain.

C72.4

Ependymoma, NOS

Malignant ependymoma not otherwise specified.

D33.2

Benign neoplasm of spinal cord

Benign tumor of the spinal cord, including some ependymomas.

Code-Specific Guidance

Decision Tree for

Follow this step-by-step guide to choose the correct ICD-10 code.

Is the ependymoma malignant?

Code Comparison

Related Codes Comparison

When to use each related code

Description
Tumor arising from ependymal cells lining ventricles, spinal cord
Astrocytoma: tumor arising from star-shaped brain cells (astrocytes)
Oligodendroglioma: slow-growing tumor from oligodendrocytes

Documentation Best Practices

Documentation Checklist
  • Ependymoma (ICD-O C72.9, ICD-10 D33.3) documented location
  • Grade of ependymoma (WHO I-III) specified
  • Size and laterality of ependymoma noted
  • Surgical resection extent documented if applicable
  • Molecular markers (if tested) clearly recorded

Coding and Audit Risks

Common Risks
  • Histology Miscoding

    Anaplastic ependymoma (grade 3) may be miscoded as a lower grade (grade 2 or 1), impacting reimbursement and treatment.

  • Site Specificity

    Failing to code the specific location (spinal, intraventricular, myxopapillary) leads to inaccurate data and potential claims issues.

  • Laterality Documentation

    Missing laterality (right, left, bilateral) for spinal ependymomas can affect coding accuracy and statistical reporting.

Mitigation Tips

Best Practices
  • Document tumor location, size, grade (ICD-10 C72.0-C72.9) for accurate coding.
  • Precise ependymoma subtype (WHO grade) crucial for treatment, compliant billing (SNOMED CT).
  • Thorough neuro exam, imaging reports improve CDI, support medical necessity reviews.
  • Multidisciplinary team review for optimal treatment, minimizes HCC coding errors.
  • Follow established guidelines for staging, grading ensures compliance, reduces denials.

Clinical Decision Support

Checklist
  • Verify neuroimaging (MRI brain/spine) confirms tumor location and characteristics.
  • Histopathology confirms ependymoma diagnosis (WHO grade).
  • Assess extent of resection/biopsy in operative report.
  • Evaluate for CSF dissemination signs/symptoms (if applicable).

Reimbursement and Quality Metrics

Impact Summary
  • Ependymoma reimbursement hinges on accurate coding (ICD-10 C72.0-C72.9) impacting hospital case mix index.
  • Coding validation crucial for ependymoma claims. Incorrect codes lead to denials, impacting revenue cycle.
  • Quality metrics for ependymoma (surgical resection extent, complications) affect hospital value-based payments.
  • Accurate ependymoma documentation vital for appropriate DRG assignment and optimal reimbursement levels.

Streamline Your Medical Coding

Let S10.AI help you select the most accurate ICD-10 codes. Our AI-powered assistant ensures compliance and reduces coding errors.

Frequently Asked Questions

Common Questions and Answers

Q: What are the key radiological features that distinguish ependymoma subtypes like spinal, intraventricular, and myxopapillary ependymoma on MRI?

A: Distinguishing ependymoma subtypes radiologically requires careful evaluation of location, signal characteristics, and enhancement patterns on MRI. Spinal ependymomas often appear as centrally located, well-circumscribed masses within the spinal canal, sometimes showing a "cap sign" of hemosiderin staining. Intraventricular ependymomas typically arise from the walls of the ventricles, frequently obstructing cerebrospinal fluid flow, and may demonstrate heterogeneous enhancement. Myxopapillary ependymomas are almost exclusively found in the filum terminale or conus medullaris region of the spine, often exhibiting a lobulated or "mulberry" appearance with prominent mucinous components. While these features can be suggestive, histopathological analysis remains the gold standard for definitive diagnosis. Explore how advanced MRI techniques, such as diffusion-weighted imaging and perfusion imaging, can further aid in characterizing these subtypes.

Q: How do current treatment guidelines for ependymoma differ for adult patients compared to pediatric patients, considering tumor location and histology?

A: Treatment guidelines for ependymoma take into account both patient age and tumor characteristics. In both adult and pediatric populations, maximal safe surgical resection remains the cornerstone of therapy. Adjuvant radiotherapy is often recommended, especially for incompletely resected tumors, higher-grade lesions, or those located in challenging anatomical locations. However, the specific radiotherapy approach may differ. For pediatric cases, especially those involving the posterior fossa, proton therapy may be considered to minimize long-term radiation-related complications. In adults, conventional radiotherapy techniques may be employed. The role of chemotherapy is less defined, primarily reserved for recurrent or refractory cases. Consider implementing molecular profiling for personalized treatment strategies, particularly in the context of clinical trials investigating novel targeted therapies for ependymoma. Learn more about current clinical trial opportunities for ependymoma patients.

Quick Tips

Practical Coding Tips
  • Code C72.0 for spinal ependymoma
  • Code C70.0 for IV ependymoma
  • Document tumor location precisely
  • Myxopapillary is C72.1
  • Consider histology for coding

Documentation Templates

Patient presents with symptoms suggestive of ependymoma, a neuroepithelial tumor arising from ependymal cells lining the ventricles and central canal of the spinal cord.  Clinical presentation varies depending on tumor location.  Intracranial ependymomas, including intraventricular ependymomas, may manifest with signs of increased intracranial pressure such as headaches, nausea, vomiting, and papilledema.  Spinal ependymomas often present with back pain, weakness, sensory changes, and gait disturbances.  Myxopapillary ependymoma, a distinct subtype typically located in the filum terminale or conus medullaris region of the spine, may present with similar symptoms.  Diagnostic workup includes magnetic resonance imaging (MRI) of the brain andor spine with and without contrast, which is crucial for visualizing the tumor and assessing its extent.  Histopathological analysis of a tissue biopsy obtained through surgical resection is essential for definitive diagnosis and grading of the ependymoma.  Differential diagnosis includes other central nervous system tumors such as astrocytoma, oligodendroglioma, and choroid plexus papilloma.  Treatment planning for ependymoma depends on factors such as tumor location, size, grade, and patient age and overall health.  Surgical resection is the primary treatment modality, aiming for maximal safe resection.  Adjuvant radiotherapy, particularly for higher-grade tumors or incompletely resected tumors, may be considered.  Chemotherapy is less commonly employed, but may be considered in specific cases, particularly for recurrent or progressive disease.  Follow-up care includes regular neurological examinations and imaging surveillance to monitor for recurrence or progression.